ABSTRACT
Objective:Analyzed the funding data of the National Natural Science Foundation of China in the field of preventive medicine from 2009 to 2019 in Nanjing Medical University, to provide scientific basis for scientific research management and decision-making.Methods:Descriptive statistics was used to reveal the status of application and funding in the field of preventive medicine, the distribution and development trends of each secondary code, the research hotspots and key themes in this field.Results:From 2009 to 2019, Nanjing Medical University submitted 566 applications in total and 230 projects were funded with a total funding of 144.03 million in the field of preventive medicine. The top five codes in the funded projects were H2610, H2607, H2603, H2611 and H2601.The funding of H2610 was mainly concentrated in four major areas including cancer, cardiovascular and cerebrovascular diseases, diabetes and hematological system diseases.H2607 funded a large amount of projects for Non-coding RNA and related pathways in recent years. Funding in the H2603 were mainly focused on tumors, glucose metabolism disorders and vitamin A requirements. The funding rate in the H2605 was 9.26%, which was significantly lower than other secondary disciplines in preventive medicine.Conclusions:The National Natural Science Foundation of Preventive Medicine in the Nanjing Medical University has a good development trend, but it also faced challenges. In the future, evidence-based scientific management will be adopted to promote the development of preventive medicine according to the characteristics of different secondary disciplines.
ABSTRACT
Objective To summarize the experience of endovascular embolization for the treatment of posterior circulation aneurysms. Methods The clinical and follow-up data of 65 patients with posterior circulation aneurysm treated with endovascular embolization in Jiangmen Central Hospital, Guangdong Province were analyzed retrospectively. Results A total of 65 patients with posterior circulation aneurysm received endovascular embolization in Jiangmen Central Hospital, including 30 females (46.2％) and 35 males (53.8％). Their age ranged from 37 to 76 years old(mean 57.3 ± 10.25).Ruptured aneurysms were found in 57 cases (87.7％) and unruptured aneurysms were found in 8 cases (12.3％). Parent arteries:22 (33.8％) in vertebral artery,23 (35.4％) in basilar artery,3 (9.2％) in posterior cerebral artery,2 (3.1％) in superior cerebellar artery, 2 (3.1％) in anterior inferior cerebellar artery, and 10 (15.4％) in posterior inferior cerebellar artery. Hunt-Hess grade:gradeⅠin 15 cases,gradeⅡin 29 cases,gradeⅢin 11 cases, grade Ⅳ in 6 cases, and grade Ⅴ in 4 cases. Twenty-one patients (32.3％) were treated with coil embolization alone,29 (44.6％) were treated with stent-assisted coil embolization, 6 (9.2％) were treated with stenting alone, and 9 (13.8％) were treated with parent artery embolization. Immediate angiography after surgery revealed that 54 patients (83.1％) were completely embolized, and 11 (16.9％) were not embolized completely. Three patients (4.6％) complicated with cerebral infarction, 2 (3.1％) had intraoperative rupture,2 had respiratory disturbance(3.1％),1 (1.5％) had hoarseness, and 1 had vitreous hemorrhage (1.5％).At discharge,the modified Glasgow outcome scale assessment showed that 53 patients (81.5％) had excellent outcome,5 (7.7％) had good outcome, and 7 (10.8％) had poor outcome. Of the patients with poor outcome, 2 (3.1％) died. Thirty-four patients (52.3％) were followed up by angiography, of whom 6 (17.6％) recurred, and 1 died of complicated cerebral infarction. Conclusion Although endovascular treatment of posterior circulation aneurysms is difficult, flexible selection of endovascular treatment may achieve good therapeutic effect.
ABSTRACT
OBJECTIVE:To put forward relevant suggestions for promoting the R&D cooperation in biomedical field in China. METHODS:Information of all invention co-patents in biomedical fields during 2000-2015 in patent database was collected,includ-ing year,patent name,application number,applicant,patent address,etc.,and descriptive statistical analysis was conducted. RE-SULTS:The number of invention co-patents in biomedical fields had been increasing year by year,and the number of invention co-patents in 2015 was about 9 times than that in 2000. Invention co-patents mainly came from Beijing,Shanghai and Guangdong,accounting for 49.1%. The top 15 applicants had 983 invention co-patents in total,accounting for 8.9% of the total number of co-patents,7 of which were enterprises. And in the invention co-patents applied by the top 10 cities for GDP ranking in 2014,inven-tion co-patents applied by enterprises,scientific research institutions(include hospitals)and universities accounted for 56.2% of all patents. CONCLUSIONS:The R&D cooperation in biomedical fields has mainly focused on a few developed provinces and cities, with low concentration of invention co-patents;the R&D cooperation is mainly led by enterprises,and hospitals have low participa-tion. The government should establish national biomedical information sharing platform,raise the R&D cooperation awareness of large-scale pharmaceutical enterprises and encourage hospitals to actively participate in R&D cooperation activities in biomedicine fields.